• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Endocare

Endocare

Endocan Corp ENDO

Last Price$0.01Day Change (%)-1.41%
Open Price$0.01Day Change ($)0.00
Day Range0.01–0.0152-Week Range0.00–0.02

As of Fri 6/24/2016 4:55:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Global Medicines for Aquaculture Market Report 2016 - Analysis, Technologies & Forecasts - Research and Markets

    Global Medicines for Aquaculture Market Report 2016 - Analysis, Technologies & Forecasts - Research and Markets

  2. Robbins Arroyo LLP: Endo International plc (ENDP) Misled Shareholders According to a Recently Filed Class Action

    Robbins Arroyo LLP: Endo International plc (ENDP) Misled Shareholders According to a Recently Filed Class Action

  3. Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Endo International plc To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

    Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Endo International plc To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

  4. IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation of Endo International plc and Advises Investors with Losses to Contact the Firm

    IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation of Endo International plc and Advises Investors with Losses to Contact the Firm

  5. SHAREHOLDER NOTICE: Goldberg Law PC Announces An Investigation of Claims Against Endo International plc And Advises Investors With Losses To Contact The Firm

    SHAREHOLDER NOTICE: Goldberg Law PC Announces An Investigation of Claims Against Endo International plc And Advises Investors With Losses To Contact The Firm

  6. CFO Network Members -- WSJ

    CFO Network Members -- WSJ

  7. Chemotherapy Induced Nausea & Vomiting Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts - Key Vendors: Merck, Tesaro, Eisai - Research and Markets

    Chemotherapy Induced Nausea & Vomiting Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts - Key Vendors: Merck, Tesaro, Eisai - Research and Markets

  8. The Market: Exaggerated Woes

    Endo Pharmaceuticals ENDP announced July 11 that it no longer expects to file a new drug application for its ketoprofen pain-relief patch by the first half of 2008 because of lackluster Phase III trial results. The drug candidate failed to show statistically significant results for pain relief in ...

  9. Health Care: 3 Picks in a More Expensive Sector

    Despite the sector looking slightly overvalued overall, we still see stocks that offer attractive valuations across the different industries.

  10. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

    Product durability, diversification, and cost synergies support strong earnings growth for this undervalued wide-moat firm.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.